Researchers at Cedars-Sinai have found that a blood test can help identify pregnant women at risk of developing a severe form of the blood pressure disorder preeclampsia.

They discovered that a specific imbalance of two placental proteins could be used to predict which women would develop preterm preeclampsia.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The researchers conducted a blinded, prospective study, which was published in the journal NEJM Evidence.

The study was conducted across 18 US hospitals in 1,014 pregnant women who are initially hospitalised for preterm hypertension.

Cedars-Sinai researchers found that a specific protein imbalance in the hospitalised pregnant women provided a path to identify their risk of developing severe preeclampsia.

They measured the ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) in pregnant women’s blood samples.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Cedars-Sinai Department of Obstetrics and Gynecology chair Sarah Kilpatrick said: “This test was significantly better than all the standard-of-care markers for preeclampsia with severe features.

“It predicted with over 90% accuracy whether the patient would develop preeclampsia with severe features or not, while the usual markers were accurate less than 75% of the time.

“Having an accurate test would help us ensure that the mother was in the right hospital for management of her care and that of her preterm baby.”

Delivery is currently the only cure for preeclampsia.

Cedars-Sinai noted that a test that can indicate a preterm pregnant woman who is likely to develop severe disease can help in optimising care.

The findings from the study are also expected to point the way for potential drug therapies for women who are at risk.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact